VFA
SIOX

Virtus Fund Advisers’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Virtus Fund Advisers’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$349K Buy
+8,286
New +$372K ﹤0.01% 405

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Virtus Fund Advisers's SIOX Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017: 8,286 shares worth $349K. The stake represents ﹤0.01% of the portfolio and ranks #405 among its holdings.

104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • Virtus Fund Advisers held 8,286 shares of Sio Gene Therapies Inc. Common Stock worth $349K as of Q4 2017.
  • Sio Gene Therapies Inc. Common Stock was a new Virtus Fund Advisers position in Q4 2017.
  • Sio Gene Therapies Inc. Common Stock made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #405 holding.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.